✨ Your Portfolio is fetched and updated from zerodha.

Tatva Chintan Pharma Chem Ltd.

TATVA

Market Cap
₹1,781 Cr.
P/E
124.58

Tatva Chintan Pharma Chem Ltd.

  • Tatva Chintan Pharma
  • Paushak
  • Ultramar & Pigments
  • TJI Speciality Chemicals
FAQs on Tatva Chintan Pharma Chem Ltd. Shareprice

Tatva Chintan Pharma has given lower returns compared to its competitors.
Tatva Chintan Pharma has grown at ~-33.17% over the last 3yrs while peers have grown at a median rate of -15.38%

Tatva Chintan Pharma is expensive when considering the PE ratio, however latest EV/EBIDTA is < 3 yr avg EV/EBIDTA.
Latest PE of Tatva Chintan Pharma is 121, while 3 year average PE is 87.63.
Also latest EV/EBITDA of Tatva Chintan Pharma is 42.43 while 3yr average is 51.73.

View FAQ's On Business
Growth Table
  • Tatva Chintan Pharma Chem Ltd.
  • Paushak
  • Ultramar & Pigments
Balance Sheet
  • Tatva Chintan Pharma Chem Ltd.
  • Paushak
  • Ultramar & Pigments
Balance Sheet Snapshot
No data available.
Fund Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end
Profit & Loss
  • Tatva Chintan Pharma Chem Ltd.
  • Paushak
  • Ultramar & Pigments
Cash Flow
  • Tatva Chintan Pharma Chem Ltd.
  • Paushak
  • Ultramar & Pigments
Cash Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
Ratios
= Dominant Factor
  • Tatva Chintan Pharma Chem Ltd.
  • Paushak
  • Ultramar & Pigments
Quarterly Results
  • Tatva Chintan Pharma Chem Ltd.
  • Paushak
  • Ultramar & Pigments
Reverse DCF
locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Rhapson method.
Learn how to use Reverse DCF
FAQs on Tatva Chintan Pharma Chem Ltd. Financials

Balance sheet of Tatva Chintan Pharma is strong.
It shouldn't have solvency or liquidity issues.

Yes, The debt of Tatva Chintan Pharma is increasing.
Latest debt of Tatva Chintan Pharma is ₹0.36 Crs as of Sep-24.
This is greater than Mar-24 when it was -₹62.23 Crs.

No, profit is decreasing.
The profit of Tatva Chintan Pharma is ₹14.3 Crs for TTM, ₹30.35 Crs for Mar 2024 and ₹45.49 Crs for Mar 2023.

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Tatva Chintan Pharma latest dividend payout ratio is 15.41% and 3yr average dividend payout ratio is 9.93%

Companies resources are allocated to majorly productive assets like Plant & Machinery

View FAQ's On Shareholding
Ideas Dashboard
Timeline
Watchlist
Portfolio
Alerts
Research
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech